Scientific deep-dive

Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head

Foundayo (orforglipron), the first non-peptide oral GLP-1 for weight loss, vs Wegovy and Zepbound: 17.2 mg labeled-dose Foundayo 11.1% vs STEP-1 Wegovy 14.9% vs SURMOUNT-1 Zepbound 20.9%, $25 vs $349 vs $449, daily pill vs weekly injection.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·12 citations

This three-way comparison is part of Weight Loss Rankings' living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

On April 1, 2026, the FDA approved Foundayo (orforglipron), the first oral non-peptide GLP-1 receptor agonist for chronic weight management[1]. It entered a market dominated by two injectable heavyweights: Wegovy (semaglutide) and Zepbound (tirzepatide 15 mg) — plus the Wegovy tablet (oral semaglutide, 1.5/4/9/25 mg), which the FDA approved on December 22, 2025 and which now shares the Wegovy label with the injection[12]. Wegovy itself now comes in both an injection (2.4 mg weekly, or 7.2 mg “Wegovy HD”) and a tablet (25 mg once daily maintenance). The drugs differ on every dimension that matters to a patient — effect size, delivery, price, titration, side effects, and access. This is the head-to-head with the trial data, the current pricing, and the case for picking each.

The 30-second answer

  • Want the biggest weight loss? Zepbound (tirzepatide 15 mg) — 20.9% mean at 72 weeks in SURMOUNT-1[3].
  • Want the cheapest drug if you have commercial insurance? Foundayo with the Lilly Savings Card — $25/month[1].
  • Want the cheapest brand-name injectable self-pay? Wegovy NovoCare at $199/month for a new patient's first two months (0.25/0.5 mg), then $349/month[7].
  • Hate needles? There are now two FDA-approved pill options: Foundayo (11.1% at the labeled max, $149–$349/month self-pay) or the Wegovy tablet (13.6% at the labeled max, $149/month at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg)[12] — both room-temperature, no refrigeration.
  • Have type 2 diabetes too? Zepbound (tirzepatide is also Mounjaro for diabetes — proven A1C reduction).

The drugs at a glance

Three FDA-approved weight management GLP-1 receptor agonists, three different mechanisms and delivery formats. For the full reference list of every FDA-approved and investigational GLP-1 medication on the US market in 2026 — including the seven T2D-only GLP-1s, the three FDA-approved generics (Hikma, Teva, Amneal), and the eight-drug investigational pipeline — see our GLP-1 medication list 2026 full reference.

  • Wegovy (semaglutide) — once-weekly subcutaneous injection (2.4 mg, or 7.2 mg “Wegovy HD”). Pure GLP-1 receptor agonist. Approved for chronic weight management since June 2021. Since a December 22, 2025 FDA approval, Wegovy is also available as a once-daily oral tablet (1.5/4/9/25 mg, 25 mg maintenance) for cardiovascular risk reduction or weight reduction in adults[12] — the tablet is not approved for pediatric weight reduction or for the MASH indication, which remain injection-only. Manufacturer: Novo Nordisk.
  • Zepbound (tirzepatide 15 mg) — once-weekly subcutaneous injection. Dual GLP-1 + GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Approved for chronic weight management since November 2023. Manufacturer: Eli Lilly.
  • Foundayo (orforglipron) — daily oral tablet. Non-peptide small-molecule GLP-1 receptor agonist (chemically very different from semaglutide and tirzepatide, which are peptide drugs). Approved for chronic weight management on April 1, 2026[1]. Manufacturer: Eli Lilly.

Effect size — the trial data, head to head

All three drugs were tested in 68-72 week phase 3 obesity trials with similar designs (placebo-controlled, mean BMI ~37, primary endpoint = percent change in body weight). The published mean weight loss results:

  • Wegovy injection (STEP-1)[2] — −14.9% mean weight loss at week 68 vs −2.4% on placebo. n=1,961. About 86% of patients lost ≥5% body weight.
  • Zepbound (SURMOUNT-1)[3] — −20.9% mean at week 72 vs −3.1% placebo. n=2,539. About 91% lost ≥5%. (5 mg dose: −16.0%; 10 mg: −19.5%; 15 mg: −20.9%.)
  • Foundayo at the FDA-labeled maximum dose of 17.2 mg in adults without type 2 diabetes — −11.1% mean weight loss at 72 weeks per the FDA-approved prescribing information[11]. ATTAIN-1, the registration trial, excluded adults with type 2 diabetes; the T2D population for orforglipron is being evaluated separately under the ATTAIN-2 / ACHIEVE program.
  • Wegovy tablet at the FDA-labeled maintenance dose of 25 mg — −13.6% mean weight loss vs −2.4% placebo (−11.2% treatment difference, 95% CI −13.6 to −8.8, p<0.0001) at 64 weeks in OASIS-4 / Study 7 (NCT05564117), the pivotal trial behind the 2026 tablet approval[12]. 76.3% of tablet-treated patients lost at least 5% of body weight vs 31.3% on placebo. This makes the tablet's labeled weight-loss claim larger than Foundayo's, though still short of either injectable.

Important note on Foundayo numbers. The ATTAIN-1 phase 3 trial[10] reports its orforglipron arms as 6, 12, and 36 mg of an investigational formulation, which the FDA label presents as the marketed 5.5, 9, and 17.2 mg tablets. The 36 mg trial arm is the 17.2 mg tablet, not a higher dose, and no 36 mg tablet is sold. The paper reports −11.2% on the treatment-regimen (ITT) estimand and −12.4% on the efficacy estimand for that arm; the label reports −11.1%.

Magnitude comparison

Mean total body-weight reduction at trial endpoint for each FDA-approved weight-management drug at its labeled maximum dose. Sources: STEP-1 (Wegovy injection), SURMOUNT-1 (Zepbound), Foundayo prescribing information (17.2 mg labeled max in adults without T2D, ATTAIN-1 population), OASIS-4/Study 7 (Wegovy tablet, 25 mg labeled maintenance dose).[2][3][11][12]

  • Foundayo — orforglipron 17.2 mg (FDA label, 72 wk)11.1 % TBWL
    labeled-max dose; the ATTAIN-1 paper reports this arm as 36 mg, with -11.2% (treatment-regimen) and -12.4% (efficacy estimand)
  • Wegovy tablet — semaglutide 25 mg oral (OASIS-4, 64 wk)13.6 % TBWL
    FDA-approved 2026 labeled maintenance dose
  • Wegovy injection — semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
  • Zepbound — tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
Mean total body-weight reduction at trial endpoint for each FDA-approved weight-management drug at its labeled maximum dose. Sources: STEP-1 (Wegovy injection), SURMOUNT-1 (Zepbound), Foundayo prescribing information (17.2 mg labeled max in adults without T2D, ATTAIN-1 population), OASIS-4/Study 7 (Wegovy tablet, 25 mg labeled maintenance dose).

Two important caveats on direct comparison:

  1. These are not head-to-head trials. STEP-1, SURMOUNT-1, and ATTAIN-1 each compared their drug against placebo, not against each other. The only published direct head-to-head between any two of these drugs is SURPASS-2[9], which compared tirzepatide vs semaglutide in type 2 diabetes (not obesity) and showed tirzepatide's superiority on both A1C and weight loss.
  2. Patient populations differ slightly across trials. STEP-1 and ATTAIN-1 enrolled patients with mean BMI ~38; SURMOUNT-1 enrolled patients with mean BMI ~38 as well, but with different prior weight loss attempts and different regional distributions. Effect sizes are comparable but not perfectly interchangeable.

Cost — the 2026 cash-pay landscape

This is where Foundayo changed the market most dramatically when it launched — though the Wegovy tablet is a second, competitively priced oral option. Pricing verified directly against the manufacturer self-pay programs (NovoCare, LillyDirect) as of November 2026:

Wegovy (injection)

  • $199/month introductory NovoCare Pharmacy self-pay price for new patients on the 0.25 mg or 0.5 mg starter dose (2 monthly fills, offer runs through December 31, 2026)
  • $349/month standard NovoCare self-pay price for 0.25/0.5/1/1.7/2.4 mg after the introductory fills end; to compare telehealth prices at the top of that ladder, see semaglutide 2.4 mg providers
  • $399/month for Wegovy HD (7.2 mg)
  • List price: $1,349.02/package. With commercial insurance: NovoCare advertises “pay as little as $25/month,” but the savings card caps at $100/month in savings — so out-of-pocket depends on your specific plan's Wegovy copay before the card applies

Wegovy (tablet), FDA-approved December 2025

  • $149/month NovoCare Pharmacy self-pay price for the 1.5 mg tablet dose ($199/month for 4 mg and $299/month for 9 mg and 25 mg)
  • Same list price as the injection: $1,349.02/package
  • Same insurance savings-card structure as the injection (pay as little as $25/month, capped at $100/month in savings)

Zepbound

  • $299/month for the 2.5 mg starter dose via LillyDirect Self Pay (price drop December 1, 2025)
  • $399/month for the 5 mg dose
  • $449/month for the 7.5 mg and higher doses
  • With commercial insurance covering Zepbound: typically $25-$100/month copay

Foundayo

  • “As low as $25/month” with the Lilly commercial-insurance savings offer (terms and conditions apply; not Medicare or Medicaid)
  • Self-pay pricing is dose-tiered, not flat: $149/month for the 0.8 mg starter dose, $149/month for 2.5 mg and $199/month for 5.5 mg (temporary reductions through December 31, 2026, from regular prices of $199 and $299), $299/month for 9 mg, and $299–$349/month for the 14.5 mg and 17.2 mg (labeled-max) doses depending on refill timing
  • No syringes, no needles, no cold chain, no shipping cost structure (it's a pill — distributed through standard pharmacy channels)

The Foundayo “as low as $25/month” commercial-insurance price is still the cheapest legal path to a brand-name FDA-approved GLP-1. But the self-pay price at the labeled-max 17.2 mg dose most patients are eventually titrated to ($299–$349/month) is now close to the Wegovy tablet's maintenance-dose pricing ($299/month at 9 mg and 25 mg) and well above the flat $149/month this article previously quoted — verify the specific dose tier's price on LillyDirect rather than assuming the starter-dose price applies at maintenance. It remains cheaper than Zepbound's maintenance-dose self-pay tiers ($449/month) and roughly comparable to the Wegovy injection's standard self-pay price ($349/month).

If you choose compounded semaglutide — top vetted providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Starting price: $169/mo (12-month plan rate)

Get started →Read review Found →

Delivery — pill vs injection

Zepbound is a subcutaneous injection delivered by single-use auto-injector pens, and Wegovy is available both as that same style of injection and, since its December 22, 2025 approval, as an oral tablet[12]. For the injection route: you inject once a week, you rotate sites, you store the pens in the refrigerator, and you travel with a cooler if you fly. See our step-by-step injection technique guide for the operational details.

Foundayo is a daily oral tablet. No injections, no needle disposal, no refrigeration, no cold chain, no airport pat-down conversation about medical-device exemptions. Per the FDA-approved prescribing information, Foundayo can be taken any time of day, with or without food, and with no water restrictions[11]. This is the central dosing-experience differentiator from Rybelsus (oral semaglutide), which is a peptide that must be taken on an empty stomach with no more than 4 ounces of water followed by a 30-minute wait before anything else by mouth. Because orforglipron is a non-peptide small molecule, it survives stomach acid and digestion without an absorption enhancer — so the Foundayo label carries none of Rybelsus's food, water, or timing restrictions. The Wegovy tablet lands in between: per its own label, it must be taken on an empty stomach in the morning with no more than 4 ounces of plain water, followed by a 30-minute wait before food, beverages, or other oral medications[12] — the same restrictive administration pattern as Rybelsus, not Foundayo's food-agnostic dosing. So among the pill options, Foundayo is the only one with zero food/water/timing restrictions; the Wegovy tablet trades a stricter morning routine for a larger labeled weight-loss effect (13.6% vs 11.1%). (Note: per an FDA discontinuation notice dated June 4, 2026, Novo Nordisk is retiring the Rybelsus-branded NDCs and replacing them with tablets branded “Ozempic” — the DailyMed label for the same SetID was updated May 2026 to read “Ozempic (oral semaglutide) tablet / Rybelsus (oral semaglutide) tablet.” It is the same T2D-only oral semaglutide product and food rule under a transitioning brand name, not a new drug.) For the full side-by-side comparison of every FDA-approved oral GLP-1 — Rybelsus/Ozempic tablet vs Foundayo vs the Wegovy tablet — see our GLP-1 pills 2026 comparison.

See our (forthcoming) how to take Foundayo guide for the full daily protocol, food restrictions, and missed-dose rules.

Titration schedule

  • Wegovy injection — 5 dose steps: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with at least 4 weeks between each dose increase per the Wegovy label. Total escalation time to maintenance: ~16-20 weeks.
  • Zepbound — 6 dose steps: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with at least 4 weeks between each dose increase per the Zepbound label. Total: ~20-24 weeks. Lower maintenance doses (5 mg or 10 mg) are also FDA-labeled and produce meaningful weight loss, so not every patient escalates to 15 mg.
  • Foundayo — 6 dose steps per the FDA label: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with at least 30 days between each dose increase per the Foundayo prescribing information [11]. Total: roughly 6 months to the labeled maximum dose. For a calendar-anchored Days 1-90 walkthrough of what each Foundayo dose feels like in practice, see our Foundayo week-by-week titration guide.
  • Wegovy tablet — 4 dose steps per the FDA label: 1.5 mg → 4 mg → 9 mg → 25 mg, with at least 30 days between each dose increase[12]. Total: roughly 4 months to the 25 mg labeled maintenance dose — faster to maintenance than Foundayo, though on a stricter fasted-morning administration schedule.

All three follow the same general principle of slow upward titration to manage GI side effects. Foundayo's steps are smaller in fractional terms, which may help tolerance.

Side effect profile — the trial-reported rates

All three drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, dyspepsia. The trial-reported rates at the maintenance dose:

  • Wegovy 2.4 mg (pooled obesity trials, FDA label)[4] — 44% nausea, 24% vomiting, 30% diarrhea, 24% constipation. 4.3% discontinued for GI side effects.
  • Zepbound 15 mg (SURMOUNT-1 and -2 pool, FDA label)[5] — 28% nausea, 13% vomiting, 23% diarrhea, 11% constipation. 4.3% discontinued for GI.
  • Foundayo 17.2 mg (Trials 1 and 2 pool, FDA label)[11] — 35% nausea, 24% vomiting, 25% diarrhea, 24% constipation. 6% discontinued for GI.

See our GLP-1 nausea management guide for the practical strategies that apply across all three drugs.

Drug interaction profile

All three carry the same boxed warning for medullary thyroid carcinoma based on rodent studies (see our cancer and MTC article), and all three are contraindicated in MEN2 and personal or family MTC history. The three labels differ on one important interaction:

  • Wegovy injection — no specific oral contraceptive warning. PK studies have not shown clinically meaningful reduction in OCP bioavailability.
  • Zepbound — the label advises patients using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after initiation and for 4 weeks after each dose escalation.
  • Wegovy tablet — the label's general drug-interactions section (7.2) notes that Wegovy delays gastric emptying and may impact absorption of concomitant oral medications, recommending increased monitoring for oral drugs with a narrow therapeutic index; it does not carry Foundayo's specific 30-day-after-dose-change contraceptive-method instruction[12].
  • Foundayo — Section 7.1 of the label specifically recommends a non-oral contraceptive method (or barrier backup) for 30 days after starting and 30 days after each dose increase. This is because Foundayo is itself an oral drug and the gastric-emptying-and- absorption interaction is more direct.
  • Foundayo + strong CYP3A4 inhibitors — when co-administered with a strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, or ritonavir-boosted antivirals), the Foundayo label caps the maximum daily dose at 9 mg once daily [11]. This is a labeled drug-drug interaction warning unique to Foundayo among the three weight-loss GLP-1s.

See our GLP-1 drug interaction checker for the full per-drug interaction database.

Pharmacokinetics and washout

  • Wegovy (injection or tablet — same semaglutide molecule) — t½ ~7 days regardless of route. Steady state in 4-5 weeks. Pre-pregnancy washout: 2 months per the label, unchanged by the 2026 tablet addition[12].
  • Zepbound — tirzepatide t½ ~5 days. Steady state in 3-4 weeks. Same 2-month pre-pregnancy washout in clinical practice.
  • Foundayo — orforglipron t½ 29-49 hours per the FDA label[11]. Steady state in approximately 5-10 days (roughly 4-5 half-lives). Much shorter washout than either semaglutide product — useful for pre-procedure hold and pre-pregnancy planning.

Use our GLP-1 washout calculator to see the residual concentration timeline for any of the three drugs.

The case for each drug

Pick Wegovy if...

  • You have insurance that covers it on formulary, OR
  • You want the injection and the lowest introductory self-pay price on a starter dose ($199/month for the first 2 fills at 0.25/0.5 mg, then $349/month standard), OR
  • You want a pill instead of a needle but still want the larger labeled weight-loss number: the Wegovy tablet (25 mg, 13.6% at 64 weeks) beats Foundayo's 11.1%, at a comparable starter self-pay price ($149/month), though on a Rybelsus-style empty-stomach schedule, OR
  • You have cardiovascular disease (the SELECT trial showed a 20% reduction in cardiovascular events on semaglutide 2.4 mg, which gave Wegovy a labeled CV benefit indication that Zepbound and Foundayo do not yet have — carried by both the injection and the tablet)

Pick Zepbound if...

  • You want the largest expected weight loss (20.9% mean in SURMOUNT-1 vs 14.9% Wegovy injection, 13.6% Wegovy tablet, and 11.1% Foundayo at each drug's labeled max dose)
  • You have type 2 diabetes (tirzepatide also exists as Mounjaro for diabetes — same drug, same manufacturer, different label)
  • You have obstructive sleep apnea (the SURMOUNT-OSA trial showed tirzepatide reduced sleep apnea severity, and Zepbound has a labeled OSA indication)
  • You were forced off Zepbound by an insurance formulary edit (CVS Caremark July 2025 swap, BMI clawback, or denial) and want to understand the realistic alternative paths plus the formulary-exception appeal — see our Zepbound alternatives 2026: Caremark-displaced edition for the rank-ordered playbook.

Pick Foundayo if...

  • You have commercial insurance and qualify for the “as low as $25/month” savings offer
  • You hate needles and would prefer a daily pill
  • You travel frequently and don't want to manage cold chain logistics
  • You expect to need short-notice surgery or a procedure (Foundayo's 29-49 hour half-life means a much shorter hold timeline than either semaglutide product, injected or oral)
  • You want a drug you can take any time of day with or without food — no empty-stomach rule, no water restrictions, no 30-minute fast before eating (this is what separates Foundayo from the Wegovy tablet, which does carry that fasted-morning rule)
  • An ~11% expected weight loss is meaningful enough for your goals (most patients with BMI ≥35 will say yes) — if you want a larger pill-form number and can tolerate a stricter morning routine, compare against the Wegovy tablet's 13.6%

What this comparison is NOT

The right drug for any individual patient depends on their full medical history, comorbidities, insurance situation, lifestyle, and tolerance for the GI side effects in the first 2-4 months. Discuss the choice with a qualified prescriber.

This article also is not a switching guide. If you are already on one of these drugs and considering a change to another, the FDA labels do not contain a dose-equivalence conversion table — switching is a prescriber decision. For the specific Foundayo ↔ Zepbound switch question (verbatim §2 dose ranges side-by-side, the cross-trial efficacy comparison, the practical re-titration logic, and the oral-contraceptive label-asymmetry that affects patients of reproductive potential), see our companion Foundayo ↔ Zepbound switch dose-equivalence guide. For broader cross-class switching (semaglutide ↔ tirzepatide, brand ↔ compounded, etc.), see the switching between GLP-1 medications guide.

Bottom line

  • All are FDA-approved for chronic weight management in adults with obesity, or overweight with a comorbidity (BMI ≥30, or ≥27 with a comorbidity, in the pivotal trials); Wegovy (both forms) additionally carries a cardiovascular-risk-reduction indication and, injection-only, a MASH indication and pediatric (12+) weight-reduction indication.
  • Effect size at each drug's labeled maximum dose: Zepbound 20.9% > Wegovy injection 14.9% > Wegovy tablet 13.6% > Foundayo 11.1%, on published mean trial data (cross-trial comparison, not head-to-head).
  • Cost (commercial insurance): both Foundayo and Wegovy (either form) advertise “as low as $25/month,” though actual out-of-pocket depends on your plan's underlying copay before the manufacturer card applies; Zepbound's commercial-insurance copay is typically $25-$100/month after PA.
  • Cost (self-pay, starter dose): Foundayo $149 ≈ Wegovy tablet $149 < Wegovy injection $199 (introductory) < Zepbound $299. At labeled-maximum/maintenance dose, self-pay pricing is closer across the board: Foundayo $299-$349, Wegovy injection $349 standard, Zepbound $449, Wegovy tablet $299 (9 and 25 mg).
  • Delivery: Foundayo is pill-only; Zepbound is injection-only; Wegovy is now available as EITHER a weekly injection OR a daily tablet (since December 2025) — the only one of the three with both options under one brand.
  • Unique features: Wegovy (both forms) has a labeled cardiovascular benefit and, injection-only, a MASH indication; Zepbound has a labeled OSA indication; Foundayo has no food/water/timing restrictions at all, the only pill in this comparison without a fasted-morning rule.

The choice between Foundayo, Wegovy (injection or tablet), and Zepbound should be made with a prescribing clinician who knows your medical history. Pricing was re-verified directly against NovoCare and LillyDirect self-pay program pages as of November 2026 and is updated as the manufacturer programs change — self-pay prices in particular change frequently and are dose-tiered, so confirm the current price for your specific dose before assuming a figure quoted here still applies. Effect size data is from the cited registration trials and reflects population means; individual outcomes vary substantially.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Our reviews

Providers that prescribe GLP-1s online

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

At each drug's FDA-labeled maximum dose: tirzepatide (Zepbound) produces the most weight loss at -20.9% in SURMOUNT-1, followed by semaglutide injection (Wegovy, 2.4 mg) at -14.9% in STEP-1, the semaglutide tablet (Wegovy, 25 mg, added to the label in 2026) at -13.6% in OASIS-4, and orforglipron (Foundayo, 17.2 mg) at -11.1% in ATTAIN-1. Zepbound and the Wegovy injection require weekly injections; Foundayo and the Wegovy tablet are both daily pills — so 'oral vs injection' is no longer the same axis as 'Wegovy vs the other two,' since Wegovy now offers both a pill and an injection under one brand.
As of October 2026, self-pay pricing for all three is dose-tiered, not flat. Foundayo: $149/month at the 0.8 mg starter dose rising to $299-$349/month at the 17.2 mg labeled-max dose (with insurance, as low as $25/month). Wegovy injection: $199/month introductory (0.25/0.5 mg, first 2 fills) rising to $349-$399/month standard. Wegovy tablet (FDA-approved December 2025): $149/month at 1.5 mg, $199/month at 4 mg, and $299/month at the 9 mg and 25 mg doses. Zepbound: $299/month at 2.5 mg rising to $449/month at 7.5 mg and above. Compounded semaglutide and tirzepatide range from roughly $99-450/month across the telehealth market. Always confirm the current price for your specific prescribed dose directly with NovoCare or LillyDirect — these self-pay tiers change frequently.
At its FDA-labeled maximum dose (17.2 mg), Foundayo produced -11.1% body weight loss in ATTAIN-1, versus -14.9% for the Wegovy injection (STEP-1) and -20.9% for tirzepatide (Zepbound, SURMOUNT-1) — roughly 74% and 53% of those magnitudes, respectively. (The ATTAIN-1 paper reports this same arm as 36 mg of the trial formulation, with -11.2% to -12.4% depending on the statistical estimand. No 36 mg tablet is sold.) The trade-off is convenience (daily oral pill, no injection, no refrigeration) and a lower self-pay price at the starting dose. At the top doses the price gap narrows: Foundayo $299-$349 versus $349 for the Wegovy injection and $449 for Zepbound.
Yes, with appropriate clinical oversight and re-titration. Switching always starts at the lowest dose of the new drug regardless of your current dose, and the full titration takes several months. There is no formal washout required. Discuss with your prescribing clinician — particular attention to GI tolerability during the re-titration period.
Side effect rates are broadly similar across all three, all dominated by GI symptoms (nausea, vomiting, diarrhea, constipation). The Foundayo (orforglipron) trials showed comparable rates to semaglutide. All three carry the same FDA boxed warning for thyroid C-cell tumors (animal data, not confirmed in humans). Discontinuation rates due to adverse events range from 6-9% across the three.
Not for maximum weight loss. Orforglipron (Foundayo), a once-daily oral non-peptide GLP-1, produced roughly 11-12% weight loss in trials (11.1% at the labeled 17.2 mg dose in the ATTAIN-1 population), while injectable tirzepatide (Zepbound) reached 20.9% in SURMOUNT-1. Orforglipron's edge is oral convenience — a daily pill with no injection, no refrigeration, and none of Rybelsus's empty-stomach or water restrictions — not magnitude. Because it is newly approved and launching, weigh the pill-vs-injection trade-off with a prescribing clinician.
Yes. The FDA approved the Wegovy tablet (1.5, 4, 9, and 25 mg strengths) on December 22, 2025, and it now shares the Wegovy label with the original weekly injection. At the 25 mg labeled maintenance dose, the Wegovy tablet produced -13.6% body weight loss vs -2.4% placebo at 64 weeks in the OASIS-4 trial (Study 7, NCT05564117) — a larger labeled effect than Foundayo's -11.1%. The trade-off is administration: the Wegovy tablet must be taken on an empty stomach in the morning with no more than 4 ounces of water and a 30-minute wait before food or other oral medication, the same restrictive pattern as Rybelsus, whereas Foundayo can be taken any time, with or without food, with no water restriction. Self-pay pricing for the Wegovy tablet starts at $149/month for the 1.5 mg dose ($199 at 4 mg), comparable to Foundayo's starter-dose price, and is $299/month at the 9 mg and 25 mg maintenance doses. Both are FDA-approved oral options; the choice comes down to tolerance for the fasted-morning routine versus the larger labeled weight-loss number.

References

  1. 1.Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss — investor press release. Eli Lilly Investor Relations. 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
  2. 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  3. 3.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  4. 4.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
  5. 5.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806s016lbl.pdf
  6. 6.Ma X, Liu R, Pratt E, Benson C, Bhattachar SN, Sloop KW, Haupt A, Karanikas C, Thomas MK. Effect of food intake on the pharmacokinetics of orforglipron, a non-peptide oral GLP-1 receptor agonist. Diabetes Therapy. 2024. PMID: 38402332.
  7. 7.Novo Nordisk Inc. NovoCare Pharmacy direct-pay program for Wegovy — patient-facing pricing tiers updated 2026. Novo Nordisk patient program. 2026. https://www.novocare.com/wegovy.html
  8. 8.Eli Lilly and Company. LillyDirect Self Pay Pharmacy Solutions for Zepbound — pricing tiers December 2025 update. Eli Lilly patient program. 2026. https://lillydirect.lilly.com/pharmacy-solutions/zepbound
  9. 9.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — head-to-head trial of the two injectables. N Engl J Med. 2021. PMID: 34170647.
  10. 10.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1, NCT05869903). Tested 6, 12, and 36 mg dose arms over 72 weeks. N Engl J Med. 2025. PMID: 40960239.
  11. 11.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information. Section 2 (dosage, 30-day minimum between dose increases, 9 mg cap with strong CYP3A4 inhibitors), Section 12.3 (pharmacokinetics, half-life 29-49 h), Section 14 (clinical studies, 17.2 mg labeled dose produces approximately −11.1% at 72 weeks in the ATTAIN-1 population without type 2 diabetes). FDA Approved Labeling. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  12. 12.Novo Nordisk Inc. WEGOVY (semaglutide) injection, solution / WEGOVY (semaglutide) tablet — US Prescribing Information, SPL version 19 (adds the oral tablet, 1.5/4/9/25 mg, for cardiovascular risk reduction or weight reduction in adults). DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Where to Buy Foundayo (Orforglipron) in 2026: The Telehealth and Pharmacy Provider Directory

Foundayo (orforglipron), approved April 1, 2026, is sold through LillyDirect, Weight Watchers Med+, Ro, Hims & Hers and Walgreens. Cash price is $149-$349/month, and the Lilly Savings Card can cut insured costs to $25/month.

9 min read

How to Get a GLP-1 Prescription in 2026: The Patient Buyer Funnel

You can get semaglutide or tirzepatide through insurance (with prior authorization), brand direct-pay (Wegovy $199-$399, Zepbound $299-$449), compounded telehealth ($150-$400/month) or the $25 oral Foundayo path. Plus red flags.

12 min read

Where to Buy Semaglutide in 2026: Verified US Provider List

There are four legitimate US channels for semaglutide in 2026: brand Wegovy or Ozempic at pharmacies with insurance, NovoCare Pharmacy direct pay, 503A compounded semaglutide through telehealth, and the insurance prior authorization path. Pricing for each and what to check.

9 min read

Where to Buy Tirzepatide in 2026: Verified US Provider List

There are four legitimate ways to get tirzepatide in 2026: Zepbound vials from LillyDirect ($299-$449/month), Zepbound pens at retail (list price up to about $1,086 per fill), Mounjaro off-label, or compounded tirzepatide via telehealth.

9 min read

Ozempic Alternatives (2026): FDA-Approved GLP-1s, Cheaper Semaglutide & Non-GLP-1 Options

The right Ozempic alternative depends on your goal. For a weight-loss-indicated GLP-1, look at Wegovy, Zepbound, Foundayo, or Saxenda. For cheaper semaglutide, NovoCare and Costco both list Wegovy at $349 a month. Non-GLP-1 options are Qsymia, Contrave, and Xenical/alli.

9 min read

Wegovy Alternatives (2026): Zepbound, Foundayo, Saxenda & Compounded Semaglutide

FDA-approved Wegovy alternatives are Zepbound for higher effect (SURMOUNT-1 -20.9% vs STEP-1 -14.9%), Foundayo as an oral option, Saxenda, and non-GLP-1 drugs such as Qsymia and Contrave. Compounded semaglutide is a cash-pay option with caveats.

12 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo (prepaid plan rate)

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

From $239/mo (12-month plan rate)

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $250/mo (starting dose)

Get started →